A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).

Trial Details

NCT ID

NCT04683679

Phase

PHASE2

Sponsor

Memorial Sloan Kettering Cancer Center

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

Pembrolizumab
Olaparib
Radiation

Locations (sample)

Basking Ridge, New Jersey, United States|40.70621,-74.54932
Middletown, New Jersey, United States|40.39428,-74.11709
Montvale, New Jersey, United States|41.04676,-74.02292
Commack, New York, United States|40.84288,-73.29289
Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of triple negat…
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 30 days prior to the d…
Histologically or cytologically-confirmed TNBC (defined as ER \<5%, PR \<5%, HER- 2-neu 0-1+ by IHC or FISH-negative or per MD discretion).
Histologically of cytologically-confirmed ER+ breast cancer, defined as ER 1-100% and HER-2/neu 0-1+ by IHC or FISH-negative

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →